Last reviewed: May 14, 2026
Last updated: May 14, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
Blood work before starting semaglutide or other GLP-1 medications serves critical safety functions: assessing kidney and liver function, thyroid status, and pancreatic health. Most patients need baseline labs, though specific tests depend on medical history and provider judgment.
Precision-wellness approaches recognize that baseline biomarkers alone don't capture the full picture. Genetic predispositions in GLP-1 and related pathways may provide context for how your metabolism responds to peptide therapy, helping providers make more informed decisions about dosing, formulation, and monitoring.
Core Metabolic Labs: Why Each Test Matters Before GLP-1 Therapy
GLP-1 medications affect glucose metabolism, appetite regulation, and gastric function—making baseline metabolic assessment essential. Fasting glucose, HbA1c, and lipid panels establish your starting point and help identify undiagnosed diabetes or cardiovascular risk.
Kidney function tests (creatinine, eGFR) are particularly important because GLP-1 drugs influence renal hemodynamics and volume status. Liver function tests reveal baseline hepatic health, while thyroid screening (TSH, free T4) is recommended because GLP-1 therapy can trigger thyroid inflammation in predisposed individuals.
Essential Lab Panel and Biomarker Framework for GLP-1 Readiness
A comprehensive pre-GLP-1 assessment typically includes metabolic markers, renal function, thyroid status, and pancreatic enzymes. The specific combination depends on your age, comorbidities, and medication history, which a qualified provider will evaluate during consultation.
| Test |
Clinical Purpose |
Why It Matters for GLP-1 |
| Fasting Glucose & HbA1c |
Assess baseline glycemic control |
Establishes diabetes status and treatment baseline |
| Comprehensive Metabolic Panel (CMP) |
Evaluate kidney, liver, electrolyte function |
GLP-1 affects renal perfusion and liver metabolism |
| Lipid Panel (Total, LDL, HDL, Triglycerides) |
Measure cardiovascular risk markers |
GLP-1 may improve lipid profile; baseline needed for comparison |
| Thyroid Screening (TSH, Free T4) |
Detect thyroid dysfunction or autoimmunity |
GLP-1 can trigger or unmask thyroid inflammation |
| Pancreatic Enzymes (Amylase, Lipase) |
Screen for pancreatic inflammation |
Baseline critical; GLP-1 carries rare pancreatitis risk |
| Calcitonin (if indicated) |
Screen for C-cell abnormalities |
Recommended for high-risk patients; animal data warrant caution |
Special Considerations: Thyroid, Kidney, and Pancreatic Screening
Thyroid assessment is crucial because GLP-1 medications can trigger thyroid autoimmunity, particularly in individuals with pre-existing thyroid disease or family history. Baseline TSH and free T4 allow providers to monitor for changes during therapy.
Kidney function requires careful evaluation: eGFR below 15 mL/min/1.73m² generally contraindicates GLP-1 use, while moderate kidney disease (eGFR 15-60) requires dose adjustment and closer monitoring. Pancreatic enzyme baseline screening helps establish your risk profile, especially if you have personal or family history of pancreatitis.
Genetic Predispositions and Biomarker Context: Personalizing Your Baseline Assessment
Beyond standard blood work, genetic factors influence how your body processes glucose, responds to appetite suppression, and metabolizes peptide compounds. Variants in GLP1R, GIPR, MC4R, and FTO genes may provide context for your baseline metabolic profile and individual treatment readiness.
The Precision Peptide Genetic Test reveals predispositions in these peptide-pathway genes, which should be interpreted with a qualified provider alongside your biomarker results. Understanding your genetic context may help inform more personalized discussions about medication choice, starting dose, and expected metabolic changes.
Provider Decision-Making: How Baseline Labs Guide Safe GLP-1 Initiation
Your provider uses baseline labs to establish absolute contraindications (personal history of medullary thyroid cancer, multiple endocrine neoplasia type 2), relative contraindications requiring closer monitoring, and safety parameters for your specific health profile.
With baseline biomarkers and genetic context in hand, qualified providers can recommend the safest formulation—compounded oral or injectable semaglutide, tirzepatide, or alternative options—and appropriate starting doses with realistic monitoring intervals. This personalized approach reduces adverse event risk and improves treatment adherence.
How PlexusDx Supports a More Personalized Approach
PlexusDx supports precision-wellness approaches by integrating baseline biomarker assessment with genetic insights into peptide pathways. Our Precision Peptide Genetic Test reveals predispositions in GLP1R, GIPR, MC4R, and FTO genes—markers that may help provide context for how your metabolism and appetite regulation function at baseline, potentially informing more personalized treatment conversations with your provider.
The test does not predict your exact response to semaglutide, tirzepatide, or other GLP-1 medications. Rather, it identifies genetic predispositions in peptide-signaling pathways that should be interpreted alongside your blood work, medical history, and clinical judgment. These insights can support a more informed baseline assessment before you start treatment.
When combined with your provider's evaluation of kidney function, thyroid status, pancreatic health, and metabolic markers, genetic predisposition data may enhance the rationale for your specific treatment choice, formulation (oral vs. injectable), and starting dose—supporting a more personalized, evidence-informed decision-making process.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Which blood tests are absolutely required before starting semaglutide?
Kidney function (eGFR, creatinine), liver function tests, thyroid screening (TSH), fasting glucose or HbA1c, and pancreatic enzymes are typically essential. Your provider may order additional tests based on your medical history and medications.
Why is kidney function testing so important before GLP-1 therapy?
GLP-1 medications affect blood flow to the kidneys and fluid balance. eGFR below 15 mL/min/1.73m² generally contraindicates therapy; moderate kidney disease requires dose adjustment and monitoring.
What does the PlexusDx Precision Peptide Genetic Test reveal about GLP-1 response?
The test identifies genetic predispositions in GLP1R, GIPR, MC4R, and FTO pathways—not exact medication response. These insights may help inform baseline assessment and provider discussion about treatment personalization.
Should I get thyroid testing even if I don't have thyroid disease?
Yes. GLP-1 medications can trigger thyroid autoimmunity in susceptible individuals. Baseline TSH and free T4 allow providers to monitor for changes during therapy, regardless of personal history.
How do genetic predispositions affect my baseline lab interpretation?
Genetic variants in peptide-signaling pathways may contextualize your baseline glucose tolerance, lipid profile, and appetite regulation. Discussing genetic predispositions with your provider alongside your blood work can support more personalized treatment decisions.
What happens if my baseline labs show kidney or thyroid problems?
This doesn't automatically exclude you from GLP-1 therapy, but your provider may recommend dose adjustment, more frequent monitoring, or alternative medications. Individual risk-benefit assessment is essential.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Cardiovascular Risks of GLP-1 Medications
Can You Drink on Semaglutide Compound? Understanding the Effects of Alcohol Consumption